Idea Transcript
(Sborník lékařský)
Multidisciplinary Biomedical Journal of the First Faculty of Medicine, Charles University in Prague
Vol. 116 (2015) Supplement
15th Central European Lung Cancer Conference
including Best of WCLC 2015 November 28–30, 2015 Prague, Czech Republic
Abstract Book
© Charles University in Prague – Karolinum Press, 2015
organized by the Czech Lung Cancer Cooperative Group Central European Lung Cancer Board under the auspices of International Association for the Study of Lung Cancer (IASLC)
The content and language editing is under the responsibility of authors.
Prague Medical Report / Vol. 116 (2015) Suppl., p. 5–6
5)
Smoking cessation workshop Epidemiology and tobacco control in Central Europe – IASLC workshop to tobacco control and smoking cessation
Smoking and lung cancer, smoking cessation among lung cancer patients G. Kovács, E. Pataki, Z. Cselkó, I. Horváth National Korányi Institute for TB and Pulmonology, Budapest, Hungary Background: Smoking is the most important risk factor for lung cancer. 85% of lung cancer patients have a history of smoking and 40–50% of patients report smoking at the time of diagnosis. Smoking however is not merely a risk factor for lung cancer, but continued smoking impairs therapeutic effectiveness, quality of life and survival. Smoking creates hypoxia in the tissues which has an adverse effect on wound healing and increases the rate of postoperative complications. Continued smoking also deteriorates the therapeutic effectiveness of radio- and chemotherapy, and increases the probability of metastases. Tobacco smoke promotes tumor development and enhanced vascularization of tumor tissues. Continued smoking increases mortality from second primary tumors, COPD and cardiovascular diseases. Methods: We recorded data from 929 lung cancer patients in our research. 53% of patients were smoking at the time of diagnosis, 25% quit previously and 22% never smoked. 57% of smokers quit after the diagnosis, while 3% of them relapsed. During the 30-month follow-up, the survival rate was significantly higher for those who quit, than those who continued to smoke (54% vs. 42% [HR: 1.29; p 3 was less than 1%. This spectrum of AE is almost identical to that observed in melanoma patients receiving pembrolizumab (14). Patients with NSCLC receiving nivolumab showed a similar pattern of AE; fatigue, myalgias, pruritus, rash, decreased appetite, nausea, loss of weight, transaminitis, vomiting and arthralgia were observed in ≥ 5% of the patients with no grade > 3 or in less than 1%. BMS-336559 (an anti PD-L1 antibody) showed the same pattern of AE; fatigue, pruritus, rash, diarrhea, nausea and arthralgia were seen in ≥ 5% with no or very rare grades > 3. 15th Central European Lung Cancer Conference including Best of WCLC 2015
21)
Prague Medical Report / Vol. 116 (2015) Suppl., p. 19–24
Table 1 – Frequency of adverse effects > 2% (% of any grade; % of grades > 3) Pembrolizumab N° patients
Nivolumab
459
389
Nivolumab + Ipilimumab (Melanoma) 94
Ipilimumab (Melanoma)
BMS-936559 (≠ tumors)
256
207
19